Areas of Interest

Autoimmune

Small molecule and bioproduct assets at all stages of development for all autoimmune diseases and with a particular emphasis on:

  • 1.
    Rheumatoid Arthritis therapies which offer the potential for significantly improved patient outcomes over current standards of care
  • 2.
    System Lupus Erythematosus (including Lupus Nephritis)
  • 3.
    Psoriasis
  • 4.
    Multiple Sclerosis
  • 5.
    Inflammatory Bowel Disease
  • 6.
    Psoriatic Arthritis
  • 7.
    Ankylosing Spondylitis

Cardiovascular

In Scope:

  • 1.
    LDL-C Reduction for Patients with Severe Hypercholesterolemia
  • 2.
    CV Event Reduction in Patients/Mixed Dyslipidemia (HDL-C)
  • 3.
    Peripheral Arterial Disease (PAD) (small vessel disease)
  • 4.
    Chronic Heart Failure (CHF)
  • 5.
    Resistant Hypertension
  • 6.
    Acute Heart Failure
  • 7.
    Event Reduction through Plaque Stabilization
  • 8.
    Stroke Prophylaxis in Atrial Fibrillation

Out of Scope (unless Phase 3):

  • 1.
    Stable Angina (no option patient)
  • 2.
    Acute Stroke
  • 3.
    Ventricular Arrhythmias (adjunct to device)
  • 4.
    Acute MI/Myocardial Protection
  • 5.
    Abdominal Aortic Aneurysm (AAA)

Diabetes

  • 1.
    Next-generation insulins (e.g., ultra-rapid, long-acting, high-concentration, glucose-responsive, novel combination, thermostable, or oral insulins)
  • 2.
    Next-generation glucagons (soluble and/or emergency)
  • 3.
    Next-generation GLP-1 mimetics (especially oral or combinations)
  • 4.
    Novel insulin sensitizers
  • 5.
    Novel insulin secretagogues
  • 6.
    Beta cell health (both T1D and T2D)
  • 7.
    Modulation of white adipose to brown adipose tissue conversion
  • 8.
    Reduction of hepatic glucose output
  • 9.
    Diabetic complications (particularly nephropathy)
  • 10.
    Other endocrine disorders (e.g., growth disorders and major unmet medical needs)
  • 11.
    Highest priority given to ‘Glucose-Plus’ agents (i.e., drugs that reduce HbA1c and elicit weight loss and/or improvements in other CV risk factors)

Musculoskeletal

Bone, Muscle, Joint Interests

Osteoporosis

  • 1.
    Novel anabolic agents for treatment of severe osteoporosis
  • 2.
    Alternative delivery opportunities for teriparatide

Muscle Atrophy

  • 1.
    Novel therapies for acute and chronic muscle atrophy
  • 2.
    Novel therapies for improvement of muscle function

Bone Healing

  • 1.
    Novel therapies for bone healing

Joint Pain

  • 1.
    Novel therapies for treatment and signs and symptoms of OA

Neuroscience

Psychiatry

  • 1.
    Depression (particularly opportunities that address sexual side effects, weight gain, co-morbidities and treatment resistant patients)
  • 2.
    Schizophrenia (particularly opportunities that address weight gain, negative symptoms and cognitive impairment)
  • 3.
    Psychosis associated with indications such as Alzheimer’s disease and Parkinson’s disease

Pain and Migraine

  • 1.
    Chronic neuropathic, inflammatory and visceral pain
  • 2.
    Migraine prophylaxis

Neurodegenerative diseases

  • 1.
    Alzheimer’s disease: Approaches that affect disease progression or modification and/or address major symptoms of the disease
  • 2.
    Parkinson’s disease: Approaches that affect disease progression or modification and/or address major symptoms of the disease

Other areas of consideration

  • 1.
    Bipolar Disorders, ADHD, sleep as a co-morbidity of depression, schizophrenia, pain and AD, Autism, PTSD, Epilepsy, Anxiety, orphan indications

Oncology

Novel targets in the following cancer pathways

  • 1.
    Immunecheckpoint / Immunotherapy approaches (exclusive of peptide vaccines and/or approaches requiring ex vivo manipulation of patient tissue(s))
  • 2.
    Antibody Drug Conjugates (ADCs) including BiSpecific ADCs
  • 3.
    BiSpecific Mabs including dual pathway inhibitors and T-cell engagers
  • 4.
    Tumor metabolism & autophagy
  • 5.
    Epigenetics
  • 6.
    Cancer stem cell & developmental pathway

Emphasis on the following cancer indications

  • 1.
    Lung - NSCLC and SCLC
  • 2.
    Gastric - mCRC, mGastric, HCC
  • 3.
    Breast malignancies
  • 4.
    Heme malignancies
  • 5.
    Epigenetics
  • 6.
    Cancer stem cell & developmental pathway

Patient Tailoring and Companion Diagnostics*

Diagnostic Imaging

  • 1.
    Novel substrate labeling PET/MRI/CT and other medical imaging technologies
  • 2.
    Molecular Diagnostics
  • 3.
    Exosomes
  • 4.
    Circulating DNA
  • 5.
    Multi-plex/multi-modal platforms
  • 6.
    Circulating tumor cell technologies
  • 7.
    CpG Methylation
  • 8.
    RNA technologies

Additional Companion Diagnostics

  • 1.
    IHC
  • 2.
    FISH
  • 3.
    Immunoassays
  • 4.
    Mass spectrometry
  • 5.
    Proteomics
  • 6.
    Emerging technologies as it relates to both R&D and companion diagnostics

Bioinformatics

  • 1.
    NGS and other genomic platforms
  • 2.
    Clinical and preclinical data
  • 3.
    Novel approaches for management and analysis of large data sets

We are interested in novel/predictive biomarkers or cutting edge platform technologies that enable patient stratification and/or drug tailoring.

*We are developing these approaches for our therapeutic areas that include:

  • 1.
    Oncology
  • 2.
    Neuroscience
  • 3.
    Autoimmune
  • 4.
    Cardiovascular

Technologies

Biology Technology Interests

  • 1.
    In vivo delivery of shRNAi
  • 2.
    Stem cells as drug discovery tools
  • 3.
    Mechanism of Action Assays for Kinases
  • 4.
    Quantitiative mass spectrometry assays
  • 5.
    Novel protein expression and purification
  • 6.
    Predictive animal models
  • 7.
    Ion channel Technologies
  • 8.
    Accordion Section 5

Biotherapeutics Technology Interests

  • 1.
    Antibody Drug Conjugate linker and conjugation technology
  • 2.
    PET-labeling of proteins
  • 3.
    Assessment of biodistribution
  • 4.
    Half-life extension of antibodies, peptides, and proteins
  • 5.
    PEG replacement technologies
  • 6.
    Microbial protein expression and production systems
  • 7.
    Antibody Fab production systems
  • 8.
    Early identification of high expressing cell lines
  • 9.
    Glycosylation technologies
  • 10.
    Bi-specific/multi-functional technologies: mAb/alternative scaffolds
  • 11.
    Peptide chemistry space: semi-synthetic, recombinant and conjugation chemistry
  • 12.
    Site-Specific Chemical Modification of Protein Research

Discovery Research Technology Interests

  • 1.
    Transporters: robust and sensitive substrate and inhibitor assays of the clinically significant uptake and export transporters
  • 2.
    Immunohistochemistry: Tissue distribution of targets and using antibodies as pharmacodynamics markers of target activation/inhibition
  • 3.
    Predictive Animal Models
  • 4.
    High throughput and quantitative imaging technologies for drug development
  • 5.
    Clinically annotated human tissues and biobanks
  • 6.
    Fragment-Based Screening

Informatics Technology Interests

  • 1.
    In vitro data analysis tools
  • 2.
    Translational informatics
  • 3.
    Data integration and warehousing services
  • 4.
    Collaboration technologies
  • 5.
    Semantic Web technologies
  • 6.
    Text analytics
  • 7.
    Predictions of human PK and drug-drug interactions from in vitro results (disease state modeling)

Drug Delivery Technology Interests

  • 1.
    Molecule and particle engineering technologies
  • 2.
    Novel/novel drug combinations in Oncology
  • 3.
    Long-acting (extended release) molecule and formulation technologies
  • 4.
    Delivery devices (novel parenteral delivery concepts and alternative delivery routes)
  • 5.
    Oral modified release - new concepts
  • 6.
    Nanomedicines and pharmaceutical nanodelivery technologies
  • 7.
    Targeted delivery technologies
  • 8.
    Drug delivery manufacturing technologies

Product Development Technology Interests

  • 1.
    Bioprocess Development
    • Large scale protein expression/production technology
    • Cell culture
    • Purification processes
  • 2.
    Formulation design
    • BBB: Delivering large proteins to the brain
    • Economical, scalable formulations
  • 3.
    Packaging
    • Engineering
    • Improved barrier materials
    • Improved process for barries (sealing, forming, etc.)
  • 4.
    Small scale process modeling
  • 5.
    Manufacturing
    • Green Chemistry
    • Reducing costs of CT Manufacturing
  • 6.
    Adaptive clinical trial design
  • 7.
    Predicting Crystallization
  • 8.
    Patient Center-Product Design
    • Compliance Technologies (including Packaging)
    • Innovation to meet needs of special groups (e.g. elderly, handicap)
    • Molecule and particle engineering technologies

Urology

Internal Medicine: Renal and Urology

  • 1.
    Chronic Kidney Disease
  • 2.
    Diabetic Nephropathy
  • 3.
    Anemia (Dialysis)
  • 4.
    Chronic Pelvic Pain Syndrome
  • 5.
    Overactive Bladder
  • 6.
    Hypogonadism
  • 7.
    Erectile Dysfunction
  • 8.
    Ejaculatory Disorders
  • 9.
    BPH/LUTS
  • 10.
    Female Sexual Dysfunction
  • 11.
    Pre-metastatic Prostate Cancer

Additional Areas of Interest

In addition to our key strategic areas of interest we are actively considering other opportunities and indications which address unmet medical needs.